Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GC-203 by Shanghai Juncell Therapeutics for Metastatic Ovarian Cancer: Likelihood of Approval
GC-203 is under clinical development by Shanghai Juncell Therapeutics and currently in Phase I for Metastatic Ovarian Cancer. According to...